GeoVax Secures April cGMP Release and Prepares H2 EMA Immune Bridging Trial
GeoVax completed release testing of GEO-MVA vaccine clinical material, with final product release scheduled for early April and sufficient supply secured for the planned immune bridging study. The company has initiated procurement outreach with national stockpile, military preparedness and outbreak response organizations ahead of its H2 EMA-driven immune bridging trial.
1. cGMP Material Release
GeoVax announced that GEO-MVA clinical supplies have completed release testing, with final product release scheduled for early April, providing sufficient cGMP material to support the upcoming immune bridging study.
2. Procurement Outreach
Outreach discussions have been initiated with organizations influencing national stockpiles, military preparedness programs and international outbreak response initiatives to secure procurement contracts for rapid GEO-MVA distribution upon regulatory authorization.
3. Immune Bridging Study Plans
The company plans to launch its EMA-guided immune bridging study in the second half of this year to demonstrate non-inferiority to an approved MVA vaccine, a key step toward marketing authorization and commercialization.